Author

B. Wildeman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:scRNA-seq· 2 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

F. Ma· 2 shared G. Garcia-Manero· 2 shared G. Montalban-Bravo· 2 shared I. Ganan-Gomez· 2 shared N. Thongon· 2 shared S. Colla· 2 shared V. Adema· 2 shared A. Rose· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Ma

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Systemic Lupus Erythematosus Serum Stimulation of Human Intestinal Organoids Induces Changes in Goblet Cell Differentiation and Mitochondrial Fitness

I. V. Hensel, S. Elias, M. Steinhauer, B. Stoll, S. Benfatto, W. Merkt, S. Krienke, H.-M. Lorenz, J. Haas, B. Wildeman, M. Resnik-Docampo

This study shows that SLE serum affects intestinal organoids by altering mucus, mitochondrial fitness, and gene expression, linking gut barrier dysfunction to autoimmune disease.

bioRxiv · Jul 4, 2023 · PreprintCell Biology

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia

G. Montalban-Bravo, F. Ma, N. Thongon, H. Yang, I. Ganan-Gomez, J. J. Rodriguez-Sevilla, V. Adema, B. Wildeman, P. P. Lockyer, Y. J. Kim, T. Tanaka, F. Darbaniyan, S. Pancholy, G. Zhang, G. Al-Atrash, , S. Colla

This study identifies MCL1 as a survival factor in RAS-mutated CMML, explaining resistance to BCL2 inhibitors and suggesting new therapeutic targets.

bioRxiv · Apr 7, 2023 · PreprintCancer Biology

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

N. Thongon, F. Ma, P. Lockyer, N. Baran, J. Liu, C. Jackson, A. Rose, B. Wildeman, M. Marchesini, V. Marchica, P. Storti, N. Giuliani, I. Ganan-Gomez, V. Adema, Y. Qing, , S. Colla

This study identifies DNA2 as a key factor in mitochondrial metabolism that enables multiple myeloma cells to survive DNA damage, showing that targeting DNA2 overcomes metabolic reprogramming and enhances therapy effectiveness.

bioRxiv · Feb 22, 2023Cancer Biology